Almatica Pharma

Executive Summary

Almatica Pharma, a U.S.-based specialty pharmaceuticals subsidiary of Alvogen, focuses on developing and commercializing innovative small molecule therapies for psychiatry and neurology, including depression, anxiety, and bipolar disorder. Leveraging a lean operational model, the company aims to efficiently bring new treatments to market. While Almatica has established a portfolio of approved products, its future growth depends on advancing its pipeline and securing regulatory approvals. The company operates in a competitive CNS landscape but benefits from Alvogen's resources and expertise. Near-term catalysts include potential FDA approvals for pipeline candidates, strategic partnerships to expand its portfolio, and launches of new formulations of existing drugs to address unmet needs.

Upcoming Catalysts (preview)

• Q4 2026FDA approval decision for a lead CNS candidate40% success
• Q3 2026Announcement of a licensing agreement for a late-stage asset50% success
• Q2 2026Launch of a new formulation of an existing neurology product70% success